Europe Blood Transfusion Diagnostics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Product, Application, and End User

The Europe blood transfusion diagnostics market is expected to grow from US$ 1,272.35 million in 2022 to US$ 1,858.70 million by 2028. It is estimated to grow at a CAGR of 6.5% from 2022 to 2028.

Populations across the world are undergoing many lifestyle changes, leading to a steady increase in the prevalence of chronic medical conditions. Continuous urbanization has been driving people toward sedentary lifestyles. The modernization of various residential, commercial, and industrial facilities has led to a reduction in physical activities among people while they are continuously under stress caused by personal, professional, and societal factors. Blood transfusion is a part of the treatment of chronic diseases such as anemia, cancer (some types), thalassemia, hemophilia, and sickle cell disease. The growing burden of chronic diseases affects public health, societies, and economies. Blood transfusion diagnostics are widely used in various surgical procedures, including cardiac surgeries and other invasive procedures. Chronic diseases, such as cancer, cardiovascular diseases, and renal disorders, are generally treated via surgical procedures, which are associated with a chance of excessive blood loss. Hence, fresh blood is infused into patients to maintain their blood levels. Blood transfusion diagnostics solutions are used during the blood infusion or reinfusion processes. Hence, the blood transfusion diagnostics market in Europe is growing with a rapid increase in the prevalence of chronic diseases.

Market Overview

Germany and the UK the key contributors to the blood transfusion diagnostics market in Europe. The market progress in these countries can be ascribed to the rising number of surgeries and transplantation procedures. In Germany, blood transfusion procedures are highly regulated. Blood services are offered by four types of organizations - state blood transfusion services, communal blood transfusion services, commercial blood centers, and plasmapheresis centers (of the plasma fractionation industry). The German Red Cross Blood Transfusion Services, Transfusion Services, and the German Society for Transfusion Medicine and Immunohematology [i.e., Deutsche Gesellschaft für Transfusionsmedizin und Immunhämatologie (DGTI)] are actively involved in providing blood transfusion services in the country. According to OECD Health Statistics, the occurrence of hip replacement surgeries in Germany was at ~315 per 100,000 people in 2019. Moreover, ~227 people per 100,000 were operated for knee replacement in 2019. Per the research article titled “Characteristics of Recipients of Red Blood Cell Concentrates in a German Federal State”, 2020, transfusion rates in Germany are significantly higher with ~50-55 RBCs/1,000 population. In Germany, in 2020, 3,518 organs were transplanted, 502 of which were living-donor transplants. The vast majority of instances (54.3%) include kidney transplants, followed by liver transplants (23.5%), lung (9.8%), heart (9.6%), pancreas (2.6%), and small intestine (0.2%) transplants. Thus, an increasing number of organ transplant procedures propel the number of blood transfusion diagnostics procedures in Germany.

Europe Blood Transfusion Diagnostics Market Segmentation

The Europe blood transfusion diagnostics market is segmented based on product, application, end user, and country. -Based on product, the Europe blood transfusion diagnostics market is bifurcated into instruments & kits and reagents. The instruments & kits segment held the larger market share in 2022.

• Based on application, the Europe blood transfusion diagnostics market is bifurcated into blood grouping and disease screening. The disease screening segment held the larger market share in 2022.
• Based on end user, the Europe blood transfusion diagnostics market is segmented into hospitals, diagnostic laboratories, blood banks, and plasma fractionation companies. The blood banks segment dominated the market in 2022.
• Based on country, the Europe blood transfusion diagnostics market has been categorized into the UK, Germany, France, Italy, Spain, and Rest of Europe. Our regional analysis states that Germany dominated the market in 2022. Abbott; BAG Diagnostics GmbH; Bio-Rad Laboratories, Inc.; DiaSorin S.p.A.; F. Hoffmann-La Roche Ltd; Grifols, S.A.; Immucor, Inc.; Ortho Clinical Diagnostics (QuidelOrtho Corporation); Quotient Limited; and Thermo Fisher Scientific Inc. are the leading companies operating in the Europe blood transfusion diagnostics market.